<DOC>
	<DOCNO>NCT02274181</DOCNO>
	<brief_summary>The purpose study investigate route ( ) elimination mass balance enclomiphene oral administration single 25 mg ( approximately equivalent [ ( ~ ] ) 500 nanocurie [ nCi ] ) dose [ 14C ] Androxal healthy adult male subject .</brief_summary>
	<brief_title>An Open-Label , Single-Dose Study Assess Absorption , Metabolism , Excretion , Mass Balance Radiolabeled Androxal Healthy Male Subjects After Oral Administration</brief_title>
	<detailed_description>The purpose study investigate route ( ) elimination mass balance enclomiphene oral administration single 25 mg ( approximately equivalent [ ( ~ ] ) 500 nanocurie [ nCi ] ) dose [ 14C ] Androxal healthy adult male subject .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<criteria>1 . Healthy , adult , male subject , 19 60 year age , inclusive , screen 2 . Continuous non smoker use nicotine containing product least 3 month prior dose 3 . Body mass index ( BMI ) ≥ 25.0 ≤ 42.0 kg/m2 screen 4 . Medically healthy clinically significant medical history , physical examination , laboratory profile , vital sign ECGs , deem PI 5 . A non vasectomized , male subject must agree use condom spermicide abstain sexual intercourse study 90 day beyond last dose study drug . ( No restriction require vasectomized male provide vasectomy perform 4 month prior study start . A male vasectomized less 4 month prior study start must follow restriction non vasectomized male ) 6 . Must agree donate sperm dose 90 day dose 7 . Understands study procedure inform consent form ( ICF ) , willing able comply protocol 1 . Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study 2 . History presence clinically significant medical psychiatric condition disease opinion PI 3 . History illness , opinion PI , might confound result study pose additional risk subject participation study 4 . History presence alcoholism drug abuse within past 2 year prior screen 5 . History presence hypersensitivity idiosyncratic reaction study drug relate compound ( e.g. , clomiphene citrate ) 6 . History presence : Renal disease history renal dysfunction ; Liver disease history liver dysfunction ; Uncontrolled thyroid adrenal dysfunction presence organic intracranial lesion pituitary tumor ; Previous history deep vein thrombosis , pulmonary embolism high risk stroke Conditions know exacerbate testosterone replacement drive androgen sensitivity 7 . Regularly less 1 bowel movement every 2 day 8 . Recent history ( within 2 week Day 1 ) abnormal bowel habit , diarrhea , loose stool , constipation 9 . Positive urine drug alcohol result screen check 10 . Positive urine cotinine screen 11 . Positive result screen HIV , HBsAg HCV 12 . Poor metabolizer CYP2D6 base genotyping CYP2D6 screening ( since CYP2D6 key enzyme enclomiphene drug metabolism ) .2 13 . Unable refrain anticipates use : Any drug , include prescription non prescription medication ( include drug know significant inhibitor CYP enzymes and/or P gp and/or OATP ) , herbal remedy , vitamin supplement begin 14 day prior dose study drug throughout study . Acetaminophen ( 2 g per 24 hour period ) Milk Magnesia ( ≤ 60 mL per day ) may permit study Any drug know significant inducer CYP enzymes and/or P gp , include St. John 's Wort , 28 day prior dose study drug throughout study . Appropriate source consult PI designee confirm lack PK/pharmacodynamics ( PD ) interaction study drug 14 . Have diet incompatible study diet , opinion PI , within 28 day prior dose study drug , throughout study 15 . Have receive radiolabeled substance expose radiation source past 12 month likely receive radiation exposure radioisotopes within next 12 month participation study would increase total exposure beyond recommended level consider safe ( i.e. , weight annual limit recommend ICRP 3000 mrem ) 16 . Donation blood significant blood loss within 56 day prior dose study drug 17 . Plasma donation within 7 day prior dose study drug 18 . Participation another clinical trial within 28 day prior dose study drug . The 28 day window derive date last blood collection dosing , whichever later , previous study Day 1 current study</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>